{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:37:56Z","timestamp":1794872276730,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82060044"],"award-info":[{"award-number":["82060044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Guangxi Province","award":["2020GXNSFAA159018"],"award-info":[{"award-number":["2020GXNSFAA159018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Div"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) is a malignancy where drug resistance often leads to relapse or refractory disease. Chemokine receptor 5 (CCR5) has emerged as a novel therapeutic target. However, the role of CCR5-antagonist Maraviroc (MVC) in M2 macrophage polarization and its potential to enhance Bortezomib sensitivity in MM has not been fully explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used human bone marrow samples, RPMI 8226 cells, and THP-1 monocytes to investigate CCL3\/CCR5 axis. ELISA measured CCL3\/CCR5 levels. Knockdown\/overexpression vectors modulated expression. Cell proliferation, apoptosis, and macrophage polarization were assessed using CCK8, flow cytometry, and transwell assays. QRT-PCR analyzed CCL3 expression, and western blotting examined PI3K\/AKT\/RhoA signaling. CCR5 was targeted via siRNAs or MVC. NOD\/SCID mouse model evaluated CCL3\/CCR5 effects on macrophage polarization and MVC\u2019s impact on Bortezomib efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CCL3, CCR5, and M2 macrophage markers are upregulated in MM patients, with CCL3\/CCR5 expression correlating with M2 macrophage polarization. Myeloma-secreted CCL3 and paracrine CCR5 significantly promoted M2 macrophage polarization by activating PI3K\/AKT\/RhoA signaling, which in turn enhanced myeloma proliferation, inhibited apoptosis, and reduced Bortezomib sensitivity. MVC inhibited M2 macrophage polarization and improved Bortezomib sensitivity in vitro and xenograft mouse myeloma models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MVC reduced macrophage polarization and enhanced Bortezomib sensitivity in MM cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13008-025-00145-1","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T13:03:51Z","timestamp":1739538231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K\/AKT\/RhoA signaling pathway in macrophages"],"prefix":"10.1186","volume":"20","author":[{"given":"Huiye","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Kashif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"145_CR1","unstructured":"Howlader N, Krapcho NA, Miller M, Brest D, Yu A, Ruhl M, Tatalovich J, Mariotto Z, Lewis A, Chen DR, Feuer HS, Cronin EJ KA, editors. SEER Cancer Statistics Review. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2018\/"},{"issue":"4","key":"145_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41571-021-00593-y","volume":"19","author":"AK Dutta","year":"2022","unstructured":"Dutta AK, Alberge JB, Sklavenitis-Pistofidis R, Lightbody ED, Getz G, Ghobrial IM. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine. Nat Rev Clin Oncol. 2022;19(4):223\u201336.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"145_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327(5):464\u201377.","journal-title":"JAMA"},{"issue":"1","key":"145_CR4","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","volume":"13","author":"JN Vo","year":"2022","unstructured":"Vo JN, Wu Y-M, Mishler J, Hall S, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill JC, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC, Ailawadhi S, Berdeja JG, Hofmeister CC, Jagannath S, Jakubowiak A, Krishnan A, Kumar S, Levy MY, Lonial S, Orloff GJ, Siegel D, Trudel S, Usmani SZ, Vij R, Wolf JL, Zonder JA, Bergsagel PL, Auclair D, Cho HJ, Robinson DR, Chinnaiyan AM. Multiple Myeloma Research, C., the genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022;13(1):3750.","journal-title":"Nat Commun"},{"issue":"13","key":"145_CR5","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.2174\/0929867328666210910124319","volume":"29","author":"A Hosseini","year":"2022","unstructured":"Hosseini A, Hamblin RM, Mirzaei H, Mirzaei RH. Role of the bone Marrow Microenvironment in Drug Resistance of Hematological Malignances. Curr Med Chem. 2022;29(13):2290\u2013305.","journal-title":"Curr Med Chem"},{"key":"145_CR6","doi-asserted-by":"crossref","unstructured":"Sharma NS, Choudhary B. Good cop, bad cop: profiling the Immune Landscape in multiple myeloma. Biomolecules 2023, 13 (11).","DOI":"10.3390\/biom13111629"},{"issue":"8","key":"145_CR7","first-page":"1261","volume":"48","author":"X WANG","year":"2019","unstructured":"WANG X, HE YC WH. MIP-1\u03b1 inhibiting osteoblast function in myeloma bone disease patients through increasing the sclerostin. Chongqing Med. 2019;48(8):1261\u20136.","journal-title":"Chongqing Med"},{"issue":"7","key":"145_CR8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1038\/leu.2011.43","volume":"25","author":"S Vallet","year":"2011","unstructured":"Vallet S, Pozzi S, Patel K, Vaghela N, Fulciniti MT, Veiby P, Hideshima T, Santo L, Cirstea D, Scadden DT, Anderson KC, Raje N. A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia. 2011;25(7):1174\u201381.","journal-title":"Leukemia"},{"issue":"5","key":"145_CR9","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1002\/jcp.26245","volume":"233","author":"M Tsubaki","year":"2018","unstructured":"Tsubaki M, Takeda T, Tomonari Y, Mashimo K, Koumoto YI, Hoshida S, Itoh T, Imano M, Satou T, Sakaguchi K, Nishida S. The MIP-1\u03b1 autocrine loop contributes to decreased sensitivity to anticancer drugs. J Cell Physiol. 2018;233(5):4258\u201371.","journal-title":"J Cell Physiol"},{"issue":"12","key":"145_CR10","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.3324\/haematol.2020.253526","volume":"106","author":"MN Zeissig","year":"2021","unstructured":"Zeissig MN, Hewett DR, Panagopoulos V, Mrozik KM, To LB, Croucher PI, Zannettino ACW, Vandyke K. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo. Haematologica. 2021;106(12):3176\u201387.","journal-title":"Haematologica"},{"key":"145_CR11","doi-asserted-by":"crossref","unstructured":"Liang Y, Bu Q, You W, Zhang R, Xu Z, Gan X, Zhou J, Qiao L, Huang T, Lu L. Single-cell analysis reveals hypoxia-induced immunosuppressive microenvironment in intrahepatic cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2024, 167276.","DOI":"10.1016\/j.bbadis.2024.167276"},{"issue":"5","key":"145_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/bjh.16881","volume":"191","author":"S Kuwahara-Ota","year":"2020","unstructured":"Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, G\u00fctschow M, Kuroda J. Lenalidomide and Pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. Br J Haematol. 2020;191(5):784\u201395.","journal-title":"Br J Haematol"},{"key":"145_CR13","doi-asserted-by":"publisher","first-page":"583084","DOI":"10.3389\/fimmu.2020.583084","volume":"11","author":"Y Pan","year":"2020","unstructured":"Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated macrophages in Tumor Immunity. Front Immunol. 2020;11:583084.","journal-title":"Front Immunol"},{"key":"145_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","volume":"11","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, Xu D. Redefining Tumor-Associated macrophage subpopulations and functions in the Tumor Microenvironment. Front Immunol. 2020;11:1731.","journal-title":"Front Immunol"},{"key":"145_CR15","doi-asserted-by":"publisher","first-page":"994319","DOI":"10.3389\/fimmu.2022.994319","volume":"13","author":"M Patysheva","year":"2022","unstructured":"Patysheva M, Frolova A, Larionova I, Afanas\u2019ev S, Tarasova A, Cherdyntseva N, Kzhyshkowska J. Monocyte programming by cancer therapy. Front Immunol. 2022;13:994319.","journal-title":"Front Immunol"},{"key":"145_CR16","doi-asserted-by":"publisher","first-page":"106709","DOI":"10.1016\/j.leukres.2021.106709","volume":"110","author":"M Sun","year":"2021","unstructured":"Sun M, Xiao Q, Wang X, Yang C, Chen C, Tian X, Wang S, Li H, Qiu S, Shu J, Shou Y, Liang Y, Xue T, Chen K. Tumor-associated macrophages modulate angiogenesis and tumor growth in a xenograft mouse model of multiple myeloma. Leuk Res. 2021;110:106709.","journal-title":"Leuk Res"},{"key":"145_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers13143597","volume":"13","author":"E Cencini","year":"2021","unstructured":"Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M. The role of Tumor-Associated macrophages in Hematologic malignancies. Cancers (Basel). 2021;13:14.","journal-title":"Cancers (Basel)"},{"issue":"08","key":"145_CR18","first-page":"978","volume":"27","author":"Y PENG","year":"2024","unstructured":"PENG Y, LI Y, WANG X. Study on the mechanisms of multiple myeloma cells promoting M2 macrophage polarization through PI3K\/AKT signaling pathway. Chin Gen Pract. 2024;27(08):978.","journal-title":"Chin Gen Pract"},{"key":"145_CR19","first-page":"3215","volume":"34","author":"WCL Xiaotao","year":"2018","unstructured":"Xiaotao. WCL, Y. J. D. H. Y. G. T. H. B. W., expression of RhoA\/ROCK1 and its clinical significance in multiple myeloma. TheJournalofPracticalMedicine. 2018;34:3215\u201323. (in chinese).","journal-title":"TheJournalofPracticalMedicine"},{"issue":"2","key":"145_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269\u201377.","journal-title":"Leukemia"},{"issue":"7","key":"145_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"145_CR22","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez A, Mart\u00ednez-Moreno M, Samaniego R, Arellano-S\u00e1nchez N, Salinas-Mu\u00f1oz L, Relloso M, Valeri A, Mart\u00ednez-L\u00f3pez J, Corb\u00ed L, Hidalgo A, Garc\u00eda-Pardo \u00c1, Teixid\u00f3 J, S\u00e1nchez-Mateos P. Evaluation of the potential therapeutic benefits of macrophage reprogramming in multiple myeloma. Blood 2016, 128 (18), 2241\u20132252.","DOI":"10.1182\/blood-2016-01-695395"},{"key":"145_CR23","doi-asserted-by":"crossref","unstructured":"Sun J, Park C, Guenthner N, Gurley S, Zhang L, Lubben B, Adebayo O, Bash H, Chen Y, Maksimos M, Muz B, Azab AK. Tumor-associated macrophages in multiple myeloma: advances in biology and therapy. J Immunother Cancer 2022, 10 (4).","DOI":"10.1136\/jitc-2021-003975"},{"issue":"5","key":"145_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10238-022-00888-z","volume":"23","author":"R Qin","year":"2023","unstructured":"Qin R, Ren W, Ya G, Wang B, He J, Ren S, Jiang L, Zhao S. Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. Clin Exp Med. 2023;23(5):1359\u201373.","journal-title":"Clin Exp Med"},{"issue":"7","key":"145_CR25","doi-asserted-by":"publisher","first-page":"6111","DOI":"10.3390\/curroncol30070455","volume":"30","author":"E Cencini","year":"2023","unstructured":"Cencini E, Sicuranza A, Ciofini S, Fabbri A, Bocchia M, Gozzetti A. Tumor-Associated macrophages in multiple myeloma: key role in Disease Biology and potential therapeutic implications. Curr Oncol. 2023;30(7):6111\u201333.","journal-title":"Curr Oncol"},{"key":"145_CR26","doi-asserted-by":"crossref","unstructured":"Korbecki J, Grochans S, Gutowska I, Barczak K, Baranowska-Bosiacka I. CC chemokines in a Tumor: a review of Pro-cancer and Anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. Int J Mol Sci 2020, 21 (20).","DOI":"10.3390\/ijms21207619"},{"issue":"12","key":"145_CR27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00262-019-02423-8","volume":"68","author":"A Vidyarthi","year":"2019","unstructured":"Vidyarthi A, Agnihotri T, Khan N, Singh S, Tewari MK, Radotra BD, Chatterjee D, Agrewala JN. Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity. Cancer Immunol Immunother. 2019;68(12):1995\u20132004.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"145_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10238-022-00888-z","volume":"23","author":"R Qin","year":"2023","unstructured":"Qin R, Ren W, Ya G, Wang B, He J, Ren S, Jiang L, Zhao S. Role of chemokines in the crosstalk between tumor and tumor-associated macrophages. Clin Experimental Med. 2023;23(5):1359\u201373.","journal-title":"Clin Experimental Med"},{"issue":"9","key":"145_CR29","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41374-020-0441-4","volume":"100","author":"T Kodama","year":"2020","unstructured":"Kodama T, Koma YI, Arai N, Kido A, Urakawa N, Nishio M, Shigeoka M, Yokozaki H. CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via akt and ERK pathways. Lab Invest. 2020;100(9):1140\u201357.","journal-title":"Lab Invest"},{"issue":"7","key":"145_CR30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/cancers12071765","volume":"12","author":"D Aldinucci","year":"2020","unstructured":"Aldinucci D, Borghese C, Casagrande N. The CCL5\/CCR5 Axis in Cancer Progression. Cancers. 2020;12(7):1765.","journal-title":"Cancers"},{"key":"145_CR31","doi-asserted-by":"publisher","first-page":"109363","DOI":"10.1016\/j.cellsig.2019.109363","volume":"63","author":"W Wang","year":"2019","unstructured":"Wang W, Chu HY, Zhong ZM, Qi X, Cheng R, Qin RJ, Liang J, Zhu XF, Zeng MS, Sun CZ. Platelet-secreted CCL3 and its receptor CCR5 promote invasive and migratory abilities of anaplastic thyroid carcinoma cells via MMP-1. Cell Signal. 2019;63:109363.","journal-title":"Cell Signal"},{"key":"145_CR32","doi-asserted-by":"crossref","unstructured":"Wu Y, Che J, Dong J, Zhang X, Deng Y, Chen W, Zhang J. CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-\u03baB\/NLRP3 signaling in a breast cancer mouse model. Neuropharmacology 2024, 109981.","DOI":"10.1016\/j.neuropharm.2024.109981"},{"key":"145_CR33","doi-asserted-by":"crossref","unstructured":"Zhou Q, Liang J, Yang T, Liu J, Li B, Li Y, Fan Z, Wang W, Chen W, Yuan S, Xu M, Xu Q, Luan Z, Xia Z, Zhou P, Huang Y, Chen L. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol Med 2022, 14(1), e14502.","DOI":"10.15252\/emmm.202114502"},{"issue":"11","key":"145_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1358\/dot.2007.43.11.1131763","volume":"43","author":"H Fadel","year":"2007","unstructured":"Fadel H, Temesgen Z, Maraviroc. Drugs Today (Barc). 2007;43(11):749\u201358.","journal-title":"Drugs Today (Barc)"}],"container-title":["Cell Division"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-025-00145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13008-025-00145-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13008-025-00145-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T13:04:01Z","timestamp":1739538241000},"score":1,"resource":{"primary":{"URL":"https:\/\/celldiv.biomedcentral.com\/articles\/10.1186\/s13008-025-00145-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1186\/s13008-025-00145-1","relation":{},"ISSN":["1747-1028"],"issn-type":[{"value":"1747-1028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval for the study was obtained from the Ethics Committee of the Affiliated Hospital of Guilin Medical University (No.20210027). The study was conducted in accordance with the tenets of the Declaration of Helsinki. The Animal Ethics Committee of Guilin Medical University (NO. GLMC202003073) approved the animal experiments, which adhered to the 8th edition of the Guidelines for the Care and Use of Experimental Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}